[en] BACKGROUND: Ambulation impairment is a major component of physical disability in multiple sclerosis (MS) and a major target of rehabilitation programs. Outcome measures commonly used to evaluate walking capacities suffer from several limitations. OBJECTIVES: To define and validate a new test that would overcome the limitations of current gait evaluations in MS and ultimately better correlate with the maximum walking distance (MWD). METHODS: The authors developed the Timed 100-Meter Walk Test (T100MW), which was compared with the Timed 25-Foot Walk Test (T25FW). For the T100MW, the subject is invited to walk 100 m as fast as he/she can. In MS patients and healthy control volunteers, the authors measured the test-retest and interrater intraclass correlation coefficient. Spearman rank correlations were obtained between the T25FW, the T100MW, the Expanded Disability Status Scale (EDSS), and the MWD. The coefficient of variation, Bland-Altman plots, the coefficient of determination, and the area under the receiver operator characteristic curve were measured. The mean walking speed (MWS) was compared between the 2 tests. RESULTS: A total of 141 MS patients and 104 healthy control volunteers were assessed. Minor differences favoring the T100MW over the T25FW were observed. Interestingly, the authors demonstrated a paradoxically higher MWS on a long (T100MW) rather than on a short distance walk test (T25FW). CONCLUSION: The T25FW and T100MW displayed subtle differences of reproducibility, variability, and correlation with MWD favoring the T100MW. The maximum walking speed of MS patients may be poorly estimated by the T25FW since MS patients were shown to walk faster over a longer distance.
Disciplines :
Neurology
Author, co-author :
Phan-Ba, Rémy ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Pace, Amy; Biogen Idec, Inc., MA, USA
CALAY, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
GRODENT, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
DOUCHAMPS, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Hyde, Robert; Biogen Idec, Inc., MA, USA
Hotermans, Christophe; Biogen Idec, Inc., MA, USA
DELVAUX, Valérie ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
HANSEN, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Moonen, Gustave ; Université de Liège - ULiège > Département des sciences cliniques > Neurologie
Belachew, Shibeshih ; Université de Liège - ULiège > Département des sciences cliniques > Neurologie
Language :
English
Title :
Comparison of the Timed 25-Foot and the 100-Meter Walk as Performance Measures in Multiple Sclerosis
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003 ; 60: 31-36 (Pubitemid 36070640)
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122 (pt 5). 871-882 (Pubitemid 29219261)
Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 ; 373: 732-738
Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000 ; 54: 802-806 (Pubitemid 30111332)
Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999 ; 5: 244-250 (Pubitemid 29405620)
Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000 ; 6: 286-290
Nieuwenhuis MM, Van Tongeren H, Sorensen PS, Ravnborg M. The six spot step test: a new measurement for walking ability in multiple sclerosis. Mult Scler. 2006 ; 12: 495-500 (Pubitemid 44132591)
Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999 ; 53: 743-750 (Pubitemid 29448294)
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846 (Pubitemid 41746873)
Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician. 1983 ; 32: 307-317
Creange A, Serre I, Levasseur M, et al. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler. 2007 ; 13: 220-223 (Pubitemid 46592775)
Lin F, Yu C, Jiang T, Li K, Chan P. Diffusion tensor tractography-based group mapping of the pyramidal tract in relapsing-remitting multiple sclerosis patients. AJNR Am J Neuroradiol. 2007 ; 28: 278-282 (Pubitemid 46281045)
Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011 ; 18 (2). 240-245
Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008 ; 14: 383-390 (Pubitemid 351676433)
Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair. 2009 ; 23: 108-116